Table 1.
Characteristics of patients with confirmed COVID-19 by positive PCR or serology
| Characteristics | COVID-19 (n = 56) | Death (n = 20) | Survival (n = 36) | P-value |
|---|---|---|---|---|
| Age (years), median (IQR) | 72.50 (57.4–80.6) | 76.5 (70–82.2) | 64.5 (54.0–78.7) | 0.041 |
| Male, n (%) | 36 (64) | 13 (65) | 23 (64) | 0.93 |
| Smoker, n (%) | 23 (41) | 9 (45) | 14 (39) | 0.99 |
| Comorbidities, n (%) | ||||
| Hypertension | 50 (89) | 18 (90) | 32 (89) | 0.99 |
| Diabetes | 21 (38) | 7 (35) | 14 (39) | 0.77 |
| Ischaemic heart disease | 20 (36) | 7 (35) | 13 (36) | 0.93 |
| History of immunosuppression | 14 (25) | 5 (25) | 9 (25) | 0.99 |
| Overweight/obesity | 13 (23) | 3 (15) | 10 (28) | 0.99 |
| Chronic heart failure | 12 (21) | 5 (25) | 7 (19) | 0.74 |
| Cancer | 10 (18) | 5 (25) | 5 (14) | 0.99 |
| Autoimmune disease | 9 (16) | 3 (15) | 6 (17) | 0.99 |
| COPD/asthma | 8 (14) | 4 (20) | 4 (11) | 0.99 |
| Peripheral arterial disease | 8 (14) | 0 (0) | 8 (22) | 0.041 |
| Immunocompromised | 7 (12) | 2 (10) | 5 (14) | 0.99 |
| Cirrhosis | 2 (3.6) | 1 (5.0) | 1 (2.8) | 0.99 |
| HIV | 1 (1.8) | 0 (0) | 1 (2.8) | 0.99 |
| Cause of CKD, n (%) | 0.422 | |||
| Unknown aetiology | 15 (27) | 6 (30) | 9 (25) | |
| Diabetic nephropathy | 13 (24) | 2 (10) | 11 (31) | |
| Glomerular disease | 12 (22) | 4 (20) | 8 (22) | |
| ADPKD | 4 (7.1) | 1 (5.0) | 3 (8.3) | |
| Other | 12 (22) | 7 (35) | 5 (14) | |
| Dialysis vintage (months), median (IQR) | 33.5 (17–75.2) | 25.5 (12.4–85.1) | 43.5 (22.0–75.2) | 0.20 |
| Diagnostic criteria for COVID-19, n (%) | ||||
| PCR | 37 (66) | 17 (85) | 20 (56) | 0.025 |
| Anti-SARS-CoV-2 positive | 19 (34) | 3 (15) | 16 (44) | |
| IgM positive | 8 (14) | 1 (5.0) | 7 (19) | |
| IgG | 2 (3.5) | 1 (5.0) | 1 (2.7) | |
| IgM + IgG | 9 (16) | 1 (5.0) | 8 (22) | |
| Symptoms, n (%) | ||||
| Asymptomatic | 15 (27) | 7 (35) | 8 (22) | 0.14 |
| Asthenia | 5 (8.9) | 1 (5.0) | 4 (11) | |
| Fever | 16 (29) | 3 (15) | 13 (36) | |
| Respiratory | 10 (18) | 6 (30) | 5 (14) | |
| Cardiovascular | 2 (3.5) | 1 (5.0) | 1 (2.7) | |
| Gastrointestinal | 8 (14) | 3 (15) | 5 (14) | |
| Chest X-ray, n/N (%) | ||||
| Normal | 22/52 (42) | 8/20 (40) | 14/32 (44) | |
| Unilateral pneumonia | 10/52 (19) | 5/20 (25) | 6/32 (19) | |
| Bilateral pneumonia | 19/52 (37) | 6/20 (30) | 12/32 (38) | |
| Analytical values, median (IQR) | ||||
| Hb (g/dL) | 11.1 (10.1–12.3) | 10.3 (9.1–11.4) | 11.5 (10.4–12.6) | 0.013 |
| Lymphocytes (/µL) | 900.0 (600.0–1200.0) | 850.0 (641.7–1000.0) | 900.0 (541.7–1258.0) | 0.813 |
| IL-6 (pg/mL) | 15.4 (5.1–42.7) | 20.5 (9.2–71.3) | 12.1 (3.3–27.2) | 0.083 |
| Ferritin (ng/mL) | 872.0 (406.2–1377.1) | 20.5 (9.2–71.3) | 12.1 (3.3–27.2) | 0.083 |
| CRP (mg/dL) | 1.6 (0.5–7.6) | 5.7 (2.4–17.1) | 1.3 (0.2–3.7) | <0.013 |
| D-dimer (µg/L) | 1442.0 (740.2–2056.0) | 1533.5 (914.5–3001.6) | 1345.0 (652.7–1976.2) | 0.303 |
| EPO dose (units/week) | 9500.0 (3000.0–18 000.0) | 8000.0 (4416.7–22 333.3) | 11 000.0 (2805.6–18 000.0) | 0.523 |
| ERI (UI/kg/week/Hb) | 11.7 (3.9–25.3) | 13.9 (3.6–25.2) | 10.4 (4.9–31.1) | 0.76 |
ADPKD, autosomal dominant polycystic kidney disease; COPD, chronic obstructive pulmonary disease; EPO, erythropoietin.